Immunobridging Trials: An Important Tool to Protect Vulnerable and Immunocompromised Patients Against Evolving Pathogens DOI Creative Commons
Pedro Cruz, Jie Min Lam, Jehad Abdalla

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 13(1), P. 19 - 19

Published: Dec. 29, 2024

Safeguarding patients from emerging infectious diseases demands strategies that prioritise patient well-being and protection. Immunobridging is an established trial methodology which has been increasingly employed to ensure protection provide clinicians with swift access vaccines. It uses immunological markers infer the effectiveness of a new drug through surrogate measure efficacy. Recently, this method also authorise novel drugs, such as COVID-19 vaccines, article explores concepts behind immunobridging trials, their advantages, issues, significance in context other diseases. Our goal improve awareness among clinicians, groups, regulators, health leaders opportunities issues immunobridging, so fewer are left without diseases, particularly major pathogens may emerge.

Language: Английский

Transformative Approaches in SARS-CoV-2 Management: Vaccines, Therapeutics and Future Direction DOI
Ankita Saha,

Shweta Choudhary,

Priyanshu Walia

et al.

Virology, Journal Year: 2025, Volume and Issue: 604, P. 110394 - 110394

Published: Jan. 11, 2025

Language: Английский

Citations

1
50-Fold Adjuvant and 20-Fold Antigen Vaccine Dose Sparing from Nanoliposome Display of a Stabilized Malarial Protein Antigen DOI
Yiting Song,

Wei‐Chiao Huang,

Danton Ivanochko

et al.

ACS Nano, Journal Year: 2025, Volume and Issue: 19(10), P. 10103 - 10112

Published: March 1, 2025

Displaying soluble vaccine protein antigens onto the surface of adjuvanted nanoliposomes can enhance magnitude elicited antibody responses. In this study, we examine approach with respect to dose sparing, for not only antigen component but also adjuvant in vaccine. Using a structurally stabilized Pfs48/45 derived malarial as model antigen, confirmed rapidly displayed on immunogenic liposomes containing cobalt porphyrin phospholipid (CoPoP; display via His-tag interaction) along immunostimulatory adjuvants monophosphoryl lipid A (MPLA) and QS-21. Mice were immunized fixed varying doses estimate extent sparing. mice vaccinated at dose, liposome-bound achieved superior IgG titers compared (nonbound) form all assessed doses, reflecting MPLA QS-21 sparing least 50-fold. The primary driver these conditions was presentation nanoparticle format, potent responses even without co-delivery within same particle, provided that liposome-displayed co-administered injection site. By keeping comparable experimental design, ∼20-fold observed liposome display. This case study illustrates potential antigen-display nanotechnologies, such CoPoP nanoliposomes, achieve substantial which could theoretically facilitate deployment future vaccines.

Language: Английский

Citations

0
Highly pathogenic avian influenza H5N1 clade 2.3.4.4b hemagglutinin and/or neuraminidase elicit immunity in a recombinant nanoparticle vaccine DOI

Qinzhe Li,

Robert Vendramelli, Thang Truong

et al.

Published: April 1, 2025

Language: Английский

Citations

0
Immunobridging Trials: An Important Tool to Protect Vulnerable and Immunocompromised Patients Against Evolving Pathogens DOI Creative Commons
Pedro Cruz, Jie Min Lam, Jehad Abdalla

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 13(1), P. 19 - 19

Published: Dec. 29, 2024

Safeguarding patients from emerging infectious diseases demands strategies that prioritise patient well-being and protection. Immunobridging is an established trial methodology which has been increasingly employed to ensure protection provide clinicians with swift access vaccines. It uses immunological markers infer the effectiveness of a new drug through surrogate measure efficacy. Recently, this method also authorise novel drugs, such as COVID-19 vaccines, article explores concepts behind immunobridging trials, their advantages, issues, significance in context other diseases. Our goal improve awareness among clinicians, groups, regulators, health leaders opportunities issues immunobridging, so fewer are left without diseases, particularly major pathogens may emerge.

Language: Английский

Citations

0